Teva Pharmaceutical Industries(NYSE) TEVA

Teva Pharmaceutical Industries Limited makes affordable medicines and health treatments. It produces generic drugs and innovative therapies for brain disorders. These products help patients manage illnesses like multiple sclerosis and asthma.

A Global Pharmacy Cabinet

• Innovative Medicines: Specialized treatments for brain and respiratory conditions like AUSTEDO for movement disorders; generated $676 million in U.S. revenue in the second quarter of 2026.
• Generic Medicines: Off-patent drugs and biosimilars, which are medicines made from biological sources; brought in $660 million in U.S. revenue in the second quarter of 2026.
• Anda Distribution: Independent service that delivers generic and brand-name drugs to hospitals, retail pharmacies, and physician offices throughout the United States.
• Active Pharmaceutical Ingredients: Chemical building blocks used to create medicines; sold to other drug manufacturers through a global business unit.

Pivoting Toward Future Growth

• Launched the "Pivot to Growth" strategy in May 2023 to focus on innovative medicines and capital allocation.
• Acquired Emalex Biosciences on June 10, 2026, for approximately $700 million to add a late-stage Tourette syndrome treatment to the pipeline.
• Established a strategic partnership in China during April 2026 to market and distribute the migraine treatment AJOVY.
• Collaborated with MedinCell to develop and sell long-acting injectable medicines, such as the schizophrenia treatment UZEDY.

How Teva Stays Competitive

Teva manages its entire product portfolio across three geographic regions to align drug development with local patient needs. It maintains a leading position in the global generic drug market while building a research pipeline focused on neuroscience and immunology.

A Snapshot of the Financials

• Revenues were $4,142 million in the second quarter of 2026, a decrease of 1% year over year.
• Operating loss reached $231 million in the second quarter of 2026, compared to operating income of $455 million in the second quarter of 2025.
• Research and development expenses reached $970 million in the second quarter of 2026, up 298% year over year.
• Cash flow from operating activities was $411 million in the second quarter of 2026, up from $227 million in the second quarter of 2025.
• Total debt decreased to $16,593 million by June 30, 2026, from $16,807 million on Dec. 31, 2025.

The Evolution of Teva

Teva is transitioning from a traditional generics manufacturer into a biopharmaceutical company focused on innovative growth engines. Its strategy balances a broad distribution reach with targeted investments in complex medicines and biosimilars.